2月10日午间公告一览：立方制药收到原料药上市申请受理通知书

Core Viewpoint - The company has received a notice of acceptance for the raw material drug Fenofibrate from the National Medical Products Administration, indicating that the product has entered the registration review stage [1] Group 1 - The acceptance of the raw material drug application signifies that the product is now in the registration review phase [1] - The approval of Fenofibrate would further enrich the company's raw material drug product pipeline [1] - The impact on the company's recent performance is not expected to be significant [1]